These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33326751)

  • 21. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
    Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L
    J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development.
    Zhang XM; Cai Y; Xiong K; Cai H; Luo XG; Feng JC; Clough RW; Struble RG; Patrylo PR; Yan XX
    Eur J Neurosci; 2009 Dec; 30(12):2271-83. PubMed ID: 20092570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.
    Arold S; Sullivan P; Bilousova T; Teng E; Miller CA; Poon WW; Vinters HV; Cornwell LB; Saing T; Cole GM; Gylys KH
    Acta Neuropathol; 2012 Jan; 123(1):39-52. PubMed ID: 22020632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer's disease mouse model with suppression of glymphatic clearance.
    Feng W; Zhang Y; Wang Z; Xu H; Wu T; Marshall C; Gao J; Xiao M
    Alzheimers Res Ther; 2020 Oct; 12(1):125. PubMed ID: 33008458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease.
    Manocha GD; Floden AM; Rausch K; Kulas JA; McGregor BA; Rojanathammanee L; Puig KR; Puig KL; Karki S; Nichols MR; Darland DC; Porter JE; Combs CK
    J Neurosci; 2016 Aug; 36(32):8471-86. PubMed ID: 27511018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice.
    Umeda T; Kimura T; Yoshida K; Takao K; Fujita Y; Matsuyama S; Sakai A; Yamashita M; Yamashita Y; Ohnishi K; Suzuki M; Takuma H; Miyakawa T; Takashima A; Morita T; Mori H; Tomiyama T
    Acta Neuropathol Commun; 2017 Jul; 5(1):59. PubMed ID: 28760161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic inhibition of phosphorylation of the translation initiation factor eIF2α does not block Aβ-dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease.
    Sadleir KR; Eimer WA; Kaufman RJ; Osten P; Vassar R
    PLoS One; 2014; 9(7):e101643. PubMed ID: 24992504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease.
    Reddy PH; Beal MF
    Trends Mol Med; 2008 Feb; 14(2):45-53. PubMed ID: 18218341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
    Manczak M; Reddy PH
    Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APP Is a Context-Sensitive Regulator of the Hippocampal Presynaptic Active Zone.
    Laßek M; Weingarten J; Wegner M; Mueller BF; Rohmer M; Baeumlisberger D; Arrey TN; Hick M; Ackermann J; Acker-Palmer A; Koch I; Müller U; Karas M; Volknandt W
    PLoS Comput Biol; 2016 Apr; 12(4):e1004832. PubMed ID: 27092780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
    Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
    Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer's Disease.
    Mirzaei M; Pushpitha K; Deng L; Chitranshi N; Gupta V; Rajput R; Mangani AB; Dheer Y; Godinez A; McKay MJ; Kamath K; Pascovici D; Wu JX; Salekdeh GH; Karl T; Haynes PA; Graham SL; Gupta VK
    Mol Neurobiol; 2019 Sep; 56(9):6017-6034. PubMed ID: 30707393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Damaged mitochondria coincide with presynaptic vesicle loss and abnormalities in alzheimer's disease brain.
    Wang W; Zhao F; Lu Y; Siedlak SL; Fujioka H; Feng H; Perry G; Zhu X
    Acta Neuropathol Commun; 2023 Mar; 11(1):54. PubMed ID: 37004141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.
    Mucke L; Masliah E; Yu GQ; Mallory M; Rockenstein EM; Tatsuno G; Hu K; Kholodenko D; Johnson-Wood K; McConlogue L
    J Neurosci; 2000 Jun; 20(11):4050-8. PubMed ID: 10818140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
    Kuznetsova E; Schliebs R
    Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imbalance in the response of pre- and post-synaptic components to amyloidopathy.
    Stephen TL; Tamagnini F; Piegsa J; Sung K; Harvey J; Oliver-Evans A; Murray TK; Ahmed Z; Hutton ML; Randall A; O'Neill MJ; Jackson JS
    Sci Rep; 2019 Oct; 9(1):14837. PubMed ID: 31619689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early neuronal loss and axonal/presynaptic damage is associated with accelerated amyloid-β accumulation in AβPP/PS1 Alzheimer's disease mice subiculum.
    Trujillo-Estrada L; Dávila JC; Sánchez-Mejias E; Sánchez-Varo R; Gomez-Arboledas A; Vizuete M; Vitorica J; Gutiérrez A
    J Alzheimers Dis; 2014; 42(2):521-41. PubMed ID: 24927710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-plaque conformational changes in Alzheimer's disease-linked Aβ and APP.
    Klementieva O; Willén K; Martinsson I; Israelsson B; Engdahl A; Cladera J; Uvdal P; Gouras GK
    Nat Commun; 2017 Mar; 8():14726. PubMed ID: 28287086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease.
    Fowler SW; Chiang AC; Savjani RR; Larson ME; Sherman MA; Schuler DR; Cirrito JR; Lesné SE; Jankowsky JL
    J Neurosci; 2014 Jun; 34(23):7871-85. PubMed ID: 24899710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.